|Summary sheet: Methallylescaline|
|Common names||Methallylescaline, MAL|
|Routes of Administration|
4-Methallyloxy-3,5-dimethoxyphenethylamine (also known as Methallylescaline, and MAL) is a synthetic psychedelic substance of the phenethylamine chemical class. It is reported to produce hallucinogenic and stimulant effects comparable to that of other mescaline analogs (e.g. allylescaline, proscaline, and escaline) when administered.
The effects of this compound were first described by Alexander Shulgin in his book PiHKAL: A Chemical Love Story. He lists the dosage range as 40mg to 60mg orally and describes the duration of action to be 8 - 12 hours.
Very little data exists about the pharmacological properties, metabolism, and toxicity of methallylescaline, and it has little history of human usage. It is advised to approach this poorly understood, long-lived psychedelic substance with the proper amount of precaution and harm reduction practices if choosing to use it.
- 1 Chemistry
- 2 Pharmacology
- 3 Subjective effects
- 4 Toxicity and harm potential
- 5 Legal issues
- 6 See also
- 7 External links
- 8 References
Methallylescaline, or 4-methallyloxy-3,5-dimethoxyphenethylamine, is a substituted phenethylamine featuring a phenyl ring bound to an amino (NH2) group through an ethyl chain. Methallylescaline contains two methoxy functional groups (CH3O-) which are attached to carbons R3 and R5 of the phenyl ring.
Methallylescaline is substituted at R4 with a methallyloxy chain. This three carbon chain consists of a R2 methyl substituted allyl group with a double bond on the terminal carbon. This chain is connected to the phenyl ring at R4 through an ether (oxygen) bridge.
Methallylescaline likely acts as a 5-HT2A partial agonist. The psychedelic effects are believed to come from methallylescaline's efficacy at the 5-HT2A receptors. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.
|| This subjective effects section is a stub.|
As such, it is still in progress and may contain incomplete or wrong information.
You can help by expanding it.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. The listed effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances and are more likely to induce a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- Spontaneous physical sensations - The "body high" of methallylescaline can be described as proportionally intense in comparison to its accompanying visual and cognitive effects. It is manifested in a number of forms including an intense soft, warm glow that grows over the body and is capable of becoming extremely physically euphoric. This is most similar to MDMA and MDA and is consistently manifested throughout the experience. This is contrasted by an intensely pleasurable yet sharp, cold electric tingling sensation which moves up and down the body. This is most similar to mescaline and is also consistently manifested throughout the trip. The final physical effect noticed throughout the experience is an intense energetic pins and needles sensation that manifests itself in the form of a continuously shifting and tingling sensation that travels up and down the body in spontaneous waves. This is most similar to 2C-I and is not entirely consistent throughout the trip.
- Physical euphoria - Relative to other psychedelics, methallylescaline has been noted for the bodily or physically euphoric aspect that is vaguely reminiscent of other phenethylamines like MDA.
- Stimulation - In terms of its effects on the physical energy levels of the tripper, methallylescaline is usually considered to be very energetic and stimulating. For example, when taken in any environment it will usually encourage physical activities such as running, walking, climbing or dancing. In comparison, other more commonly used psychedelics such as psilocin are generally sedating and relaxed.
- Nausea - Nausea is commonly reported when consumed in moderate to high doses and either passes instantly once the tripper has vomited or gradually fades by itself as the peak sets in.
- Tactile enhancement - Feelings of enhanced tactile sensations are consistently present at moderate levels throughout most methallylescaline experiences. If Level 8A geometry is reached, an intense sensation of suddenly becoming aware of and being able to feel every single nerve ending across a person's entire body all at once is consistently present.
- Appetite suppression
- Frequent urination
- Increased heart rate
- Increased libido
- Muscle contractions
- Pupil dilation
- Drifting (melting, breathing, morphing and flowing)
- Colour shifting
- Depth perception distortions
- Perspective distortions
- Symmetrical texture repetition
- After images
- Brightness alteration
The visual geometry that is present throughout this trip can be described as similar in appearance to that of ayahuasca or psilocin in the sense that its geometry is structured in its organization as well as natural and organic in style. However, in terms of its bright color palette and sharp edges, it is also similar to that of LSD, 2C-B and 2C-I.
The geometry can be comprehensively described as:
- Organic in geometric style
- Equally abstract and algorithmic in appearance
- Intricate in complexity
- Structured in its organization
- Fast in speed
- Smooth in motion
- Equally large and small in appearance - It has a variable size that spontaneously changes between large and small in appearance.
- Multicoloured in scheme
- Glossy in colour
- Sharp and angular in its corners
- Level 8B - While the geometry produced by mescaline has yet to be fully characterized, the geometry gives off certain attributes which are significantly more likely to result in states of level 8A visual geometry over level 8B at higher doses.
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational methallylescaline use do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because methallylescaline is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried methallylescaline suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption. It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
Methallylescaline is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of methallylescaline are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). Methallylescaline presents cross-tolerance with all psychedelics, meaning that after the consumption of methallylescaline all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- United Kingdom - It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016.
- United States - Methallylescaline is unscheduled in the U.S., but may be illegal via the Federal Analogue Act.
- #99 MAL: Methallylescaline; 3,5-Dimethoxy-4-methallyloxyphenethylamine (PiHKAL) | http://isomerdesign.com/PiHKAL/read.php?id=99&domain=pk |
- Psychoactive Substances Act 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/ukpga/2016/2/contents/enacted